Forman Mark S 4
4 · Passage BIO, Inc. · Filed Feb 13, 2024
Insider Transaction Report
Form 4
Forman Mark S
Chief Medical Officer
Transactions
- Exercise/Conversion
Restricted Stock Unit
2024-02-10−5,000→ 10,000 total→ Common Stock (5,000 underlying) - Award
Employee Stock Option (right to buy)
2021-08-16+130,000→ 130,000 totalExercise: $10.84Exp: 2031-08-15→ Common Stock (130,000 underlying) - Award
Restricted Stock Unit
2022-02-10+15,000→ 15,000 total→ Common Stock (15,000 underlying) - Exercise/Conversion
Common Stock
2024-02-10+5,000→ 50,269 total - Sale
Common Stock
2024-02-13$0.97/sh−1,638$1,589→ 48,631 total - Award
Employee Stock Option (right to buy)
2022-02-10+25,000→ 25,000 totalExercise: $4.52Exp: 2032-02-09→ Common Stock (25,000 underlying)
Footnotes (5)
- [F1]Restricted stock units ("RSUs") convert into common stock on a one-for-one basis.
- [F2]The sale reported on this Form 4 represents an Issuer mandated sale by the Reporting Person to satisfy tax withholding obligations in connection with the vesting and settlement of RSUs; it does not represent a discretionary trade by the Reporting Person. Pursuant to the Issuer's equity incentive plan, an award recipient's tax withholding obligations must be funded by a "sell to cover" transaction.
- [F3]The stock option vests as to 25% of the total shares on August 16, 2022, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
- [F4]The stock option vests as of 1/48 of the total shares monthly beginning on March 10, 2022 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
- [F5]1/3 of the RSUs will vest on February 10, 2024 and 2/3 of the RSUs will vest on February 10, 2025, subject to the Reporting Person's continued service to the Issuer on each vesting date.